Publications by authors named "G Lerzo"
Article Synopsis
- A study investigated the long-term survival benefits of adding lapatinib to chemotherapy and trastuzumab in HER2-positive early breast cancer, comparing rates of pathological complete response (pCR).* -
- Over a ten-year follow-up, patients receiving the combination treatment showed event-free survival (EFS) rates of 67% and overall survival (OS) rates of 80%, with pCR linked to significantly better EFS and OS.* -
- The findings indicate that neoadjuvant anti-HER2 therapy provides lasting survival advantages for patients, particularly for those achieving pCR, without any new safety issues reported.*
Introduction: Pazopanib is approved in Latin America as first targeted therapy for patients with metastatic renal cell carcinoma (mRCC).
Methods: A retrospective chart review of adult patients with mRCC who initiated pazopanib as first targeted therapy between January 2011 and March 2016 was conducted among oncology care centers in Argentina, Brazil, Chile, Colombia, and Mexico. Patient characteristics, treatment patterns, overall survival (OS), progression-free survival (PFS), and adverse events were summarized.
Introduction: The purpose of this study was to evaluate the safety and efficacy of ixabepilone plus capecitabine in patients with metastatic or locally advanced triple-negative breast cancer (TNBC).
Patients And Methods: We conducted a pooled analysis of patients with TNBC enrolled in 2 phase III trials (NCT00080301 and NCT00082433), pretreated or resistant to an anthracycline and a taxane. In each study, patients were randomized to receive ixabepilone 40 mg/m (3-hour intravenous infusion, day 1), plus oral capecitabine 1000 mg/m twice daily (days 1-14), or capecitabine alone 1250 mg/m twice daily (days 1-14), every 3 weeks.
Background: Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2(+)) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs, are warranted.
Patients And Methods: In the present phase II, multicenter study, patients with HER2(+) MBC with progression after taxane were randomized between L, 1250 mg, combined with C, 2000 mg/m(2) on days 1 to 14 (LC), vinorelbine (V), 25 mg/m(2) on days 1 and 8 (LV), or gemcitabine (G), 1000 mg/m(2) on days 1 and 8 (LG), every 21 days.
Background: Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.
Methods: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited women with HER2-positive, trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy.